Condition: Diabetic Nephropathy · Diabetic Kidney Disease · Sponsor: NephroGenex, Inc.
The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| CSG Investigational Site (#157) | Birmingham, Alabama, United States | — |
| CSG Investigational Site (#130) | Phoenix, Arizona, United States | — |
| CSG Investigational Site (#150) | Phoenix, Arizona, United States | — |
| CSG Investigational Site (#145) | Prescott, Arizona, United States | — |
| CSG Investigational Site (#142) | Tucson, Arizona, United States | — |
| CSG Investigational Site (#160) | Los Angeles, California, United States | — |
| CSG Investigational Site (#143) | Riverside, California, United States | — |
| CSG Investigational Site (#159) | Roseville, California, United States | — |
| CSG Investigational Site (#153) | Arvada, Colorado, United States | — |
| CSG Investigational Site (#118) | Aurora, Colorado, United States | — |
| CSG Investigational Site (#120) | Westminster, Colorado, United States | — |
| CSG Investigational Site (#158) | Waterbury, Connecticut, United States | — |
+ 125 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02156843